Shenzhen Salubris Pharmaceuticals
Shenzhen Salubris Pharmaceuticals Co., Ltd. is a professional pharmaceutical enterprise rooted in China and devoted to improving health worldwide.
Launch date
Employees
Market cap
AUD7.7b
Enterprise valuation
AUD7.4b (Public information from Sep 2024)
Share price
CNY31.66 002294.SZ
Shenzhen Guangdong (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.7b | 3.1b | 3.5b | 3.4b | 4.0b | 4.7b | 5.5b |
| % growth | (39 %) | 12 % | 14 % | (3 %) | 20 % | 16 % | 17 % |
| EBITDA | 595m | 1.1b | 1.1b | 1.1b | 1.1b | 1.2b | 1.4b |
| % EBITDA margin | 22 % | 35 % | 31 % | 31 % | 26 % | 25 % | 25 % |
| Profit | 60.9m | 534m | 637m | 580m | 648m | 752m | 925m |
| % profit margin | 2 % | 17 % | 18 % | 17 % | 16 % | 16 % | 17 % |
| EV / revenue | 10.5x | 8.8x | 9.7x | 10.2x | 8.0x | 6.7x | 5.8x |
| EV / EBITDA | 48.2x | 25.3x | 30.9x | 32.5x | 30.6x | 26.3x | 23.4x |
| R&D budget | 371m | 357m | 534m | 409m | - | - | - |
| R&D % of revenue | 14 % | 12 % | 15 % | 12 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | CNY1.8b | Post IPO Equity | |
| Total Funding | - | ||
Related Content
Recent News about Shenzhen Salubris Pharmaceuticals
Edit
exited
ACQUISITION by Shenzhen Salubris Pharmaceuticals Jan 2016
